Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 69 Neoplasms 21 Breast Neoplasms 21 Fallopian Tube Neoplasms 18 Prostatic Neoplasms 15 Neoplasm Metastasis 9 Pancreatic Neoplasms 8 Endometrial Neoplasms 8 Carcinoma, Ovarian Epithelial 8 Glioblastoma 7 Triple Negative Breast Neoplasms 6 Lung Neoplasms 5 Small Cell Lung Carcinoma 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Mesothelioma 3 Melanoma 3 Head and Neck Neoplasms 3 Cystadenocarcinoma, Serous 3 Cholangiocarcinoma 3 Carcinoma 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Stomach Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Ovarian Diseases 2

Interventions

spartalizumab 1 sapropterin 1 penpulimab 1 niraparib 1 anlotinib 1 Taxes 1 Leucovorin 1 Ipilimumab 1 IFL protocol 1 Gemcitabine 1 Decitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Adenocarcinoma Metastatic × niraparib × Clear all

NCT06747845 2025-09-16

ParpVax2

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡